#WRN inhibitor

All articles tagged with "WRN inhibitor"

A phase 1 trial reported in Nature Medicine tested inhibition of the Werner syndrome helicase (WRN) in cancers with microsatellite instability.
The approach relies on synthetic lethality: MSI tumors already lack mismatch repair, and blocking WRN removes a second pathway they depend on.
WRN is a helicase involved in DNA replication, repair, and genome stability, and MSI cells appear more reliant on it than healthy cells.
Phase 1 studies primarily establish safety, tolerability, dosing and preliminary target engagement rather than proven efficacy.

DT Editorial Team·Sep 29, 2026·via nature.com

Nature Medicine published a phase 1 trial of RO7589831, a first-in-class Werner helicase inhibitor, in advanced MSI-high solid tumors on 29 September 2026.
The report covers the dose-escalation stage, focused on safety, tolerability, pharmacokinetics, and dose selection.
The mechanism rests on synthetic lethality: MSI-high cancer cells depend on WRN function in a way that mismatch repair-proficient cells do not.
Dose-escalation data are early and exploratory, so no efficacy conclusions can be drawn from this stage alone.

DT Editorial Team·Sep 29, 2026·via nature.com